NB012664
Thyroid Peroxidase Antibody (TPO/1922), DyLight 550, Novus Biologicals™
Manufacturer: Novus Biologicals
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | NB012664-Each-of-1 | In Stock | ₹ 55,271.76 |
NB012664 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 55,271.76
GST (18%): ₹ 9,948.917
Total Price: ₹ 65,220.677
Antigen
Thyroid Peroxidase
Classification
Monoclonal
Conjugate
DyLight 550
Formulation
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols
TPO
Immunogen
Recombinant fragment of human Thyroid Peroxidase (around aa 685-804) (Exact sequence is proprietary) (Uniprot: P07202)
Quantity
0.1 mL
Research Discipline
Lipid and Metabolism
Test Specificity
Thyroperoxidase (TPO) is a 933-amino acid, type I transmembrane glycoprotein that plays a key role in thyroid gland function and autoimmunity. It is present as a dimer on the apical surface of thyroid follicular cells. TPO functions in the iodination of tyrosine residues in thyroglobulin and phenoxy-ester formation between pairs of iodinated tyrosines to generate the thyroid hormones, thyroxine and triiodothyronine. Mutations in this gene are associated with several disorders of thyroid hormonogenesis, including congenital hypothyroidism, congenital goiter, and thyroid hormone organification defect IIA. Malignant thyroid tumors exhibit an anomaly in TPO resulting in lower affinity for anti-TPO. This antibody may aid in the differentiation between benign and malignant thyroid tumors.
Content And Storage
Store at 4°C in the dark.
Applications
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone
TPO/1922
Dilution
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias
EC 1.11.1, MSA, TDH2A, thyroid microsomal antigen, thyroid peroxidase, thyroperoxidase, TPXEC 1.11.1.8
Host Species
Mouse
Purification Method
Protein A or G purified
Regulatory Status
RUO
Primary or Secondary
Primary
Target Species
Human
Isotype
IgG1 κ
Description
- Thyroid Peroxidase Monoclonal specifically detects Thyroid Peroxidase in Human samples
- It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.
Compare Similar Items
Show Difference
Antigen: Thyroid Peroxidase
Classification: Monoclonal
Conjugate: DyLight 550
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TPO
Immunogen: Recombinant fragment of human Thyroid Peroxidase (around aa 685-804) (Exact sequence is proprietary) (Uniprot: P07202)
Quantity: 0.1 mL
Research Discipline: Lipid and Metabolism
Test Specificity: Thyroperoxidase (TPO) is a 933-amino acid, type I transmembrane glycoprotein that plays a key role in thyroid gland function and autoimmunity. It is present as a dimer on the apical surface of thyroid follicular cells. TPO functions in the iodination of tyrosine residues in thyroglobulin and phenoxy-ester formation between pairs of iodinated tyrosines to generate the thyroid hormones, thyroxine and triiodothyronine. Mutations in this gene are associated with several disorders of thyroid hormonogenesis, including congenital hypothyroidism, congenital goiter, and thyroid hormone organification defect IIA. Malignant thyroid tumors exhibit an anomaly in TPO resulting in lower affinity for anti-TPO. This antibody may aid in the differentiation between benign and malignant thyroid tumors.
Content And Storage: Store at 4°C in the dark.
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TPO/1922
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EC 1.11.1, MSA, TDH2A, thyroid microsomal antigen, thyroid peroxidase, thyroperoxidase, TPXEC 1.11.1.8
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Isotype: IgG1 κ
Antigen:
Thyroid Peroxidase
Classification:
Monoclonal
Conjugate:
DyLight 550
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TPO
Immunogen:
Recombinant fragment of human Thyroid Peroxidase (around aa 685-804) (Exact sequence is proprietary) (Uniprot: P07202)
Quantity:
0.1 mL
Research Discipline:
Lipid and Metabolism
Test Specificity:
Thyroperoxidase (TPO) is a 933-amino acid, type I transmembrane glycoprotein that plays a key role in thyroid gland function and autoimmunity. It is present as a dimer on the apical surface of thyroid follicular cells. TPO functions in the iodination of tyrosine residues in thyroglobulin and phenoxy-ester formation between pairs of iodinated tyrosines to generate the thyroid hormones, thyroxine and triiodothyronine. Mutations in this gene are associated with several disorders of thyroid hormonogenesis, including congenital hypothyroidism, congenital goiter, and thyroid hormone organification defect IIA. Malignant thyroid tumors exhibit an anomaly in TPO resulting in lower affinity for anti-TPO. This antibody may aid in the differentiation between benign and malignant thyroid tumors.
Content And Storage:
Store at 4°C in the dark.
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TPO/1922
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EC 1.11.1, MSA, TDH2A, thyroid microsomal antigen, thyroid peroxidase, thyroperoxidase, TPXEC 1.11.1.8
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Isotype:
IgG1 κ
Antigen: Thyroid Peroxidase
Classification: Monoclonal
Conjugate: DyLight 350
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TPO
Immunogen: Recombinant fragment of human Thyroid Peroxidase (around aa 685-804) (Exact sequence is proprietary) (Uniprot: P07202)
Quantity: 0.1 mL
Research Discipline: Lipid and Metabolism
Test Specificity: Thyroperoxidase (TPO) is a 933-amino acid, type I transmembrane glycoprotein that plays a key role in thyroid gland function and autoimmunity. It is present as a dimer on the apical surface of thyroid follicular cells. TPO functions in the iodination of tyrosine residues in thyroglobulin and phenoxy-ester formation between pairs of iodinated tyrosines to generate the thyroid hormones, thyroxine and triiodothyronine. Mutations in this gene are associated with several disorders of thyroid hormonogenesis, including congenital hypothyroidism, congenital goiter, and thyroid hormone organification defect IIA. Malignant thyroid tumors exhibit an anomaly in TPO resulting in lower affinity for anti-TPO. This antibody may aid in the differentiation between benign and malignant thyroid tumors.
Content And Storage: Store at 4°C in the dark.
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TPO/1922
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EC 1.11.1, MSA, TDH2A, thyroid microsomal antigen, thyroid peroxidase, thyroperoxidase, TPXEC 1.11.1.8
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Isotype: IgG1 κ
Antigen:
Thyroid Peroxidase
Classification:
Monoclonal
Conjugate:
DyLight 350
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TPO
Immunogen:
Recombinant fragment of human Thyroid Peroxidase (around aa 685-804) (Exact sequence is proprietary) (Uniprot: P07202)
Quantity:
0.1 mL
Research Discipline:
Lipid and Metabolism
Test Specificity:
Thyroperoxidase (TPO) is a 933-amino acid, type I transmembrane glycoprotein that plays a key role in thyroid gland function and autoimmunity. It is present as a dimer on the apical surface of thyroid follicular cells. TPO functions in the iodination of tyrosine residues in thyroglobulin and phenoxy-ester formation between pairs of iodinated tyrosines to generate the thyroid hormones, thyroxine and triiodothyronine. Mutations in this gene are associated with several disorders of thyroid hormonogenesis, including congenital hypothyroidism, congenital goiter, and thyroid hormone organification defect IIA. Malignant thyroid tumors exhibit an anomaly in TPO resulting in lower affinity for anti-TPO. This antibody may aid in the differentiation between benign and malignant thyroid tumors.
Content And Storage:
Store at 4°C in the dark.
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TPO/1922
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EC 1.11.1, MSA, TDH2A, thyroid microsomal antigen, thyroid peroxidase, thyroperoxidase, TPXEC 1.11.1.8
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Isotype:
IgG1 κ
Antigen: TRAF-1
Classification: Monoclonal
Conjugate: Alexa Fluor 350
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TRAF1
Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity: 0.1 mL
Research Discipline: Apoptosis, Cancer, Cytokine Research
Test Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage: Store at 4°C in the dark.
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TRAF1/2770
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Isotype: IgG1 κ
Antigen:
TRAF-1
Classification:
Monoclonal
Conjugate:
Alexa Fluor 350
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TRAF1
Immunogen:
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity:
0.1 mL
Research Discipline:
Apoptosis, Cancer, Cytokine Research
Test Specificity:
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage:
Store at 4°C in the dark.
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TRAF1/2770
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Isotype:
IgG1 κ
Antigen: TRAF-1
Classification: Monoclonal
Conjugate: Alexa Fluor 405
Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols: TRAF1
Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity: 0.1 mL
Research Discipline: Apoptosis, Cancer, Cytokine Research
Test Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage: Store at 4°C in the dark.
Applications: Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone: TRAF1/2770
Dilution: Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias: EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species: Mouse
Purification Method: Protein A or G purified
Regulatory Status: RUO
Primary or Secondary: Primary
Target Species: Human
Isotype: IgG1 κ
Antigen:
TRAF-1
Classification:
Monoclonal
Conjugate:
Alexa Fluor 405
Formulation:
50mM Sodium Borate with 0.05% Sodium Azide
Gene Symbols:
TRAF1
Immunogen:
Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
Quantity:
0.1 mL
Research Discipline:
Apoptosis, Cancer, Cytokine Research
Test Specificity:
This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
Content And Storage:
Store at 4°C in the dark.
Applications:
Immunohistochemistry, Immunohistochemistry (Paraffin)
Clone:
TRAF1/2770
Dilution:
Immunohistochemistry, Immunohistochemistry-Paraffin
Gene Alias:
EBI6MGC:10353, Epstein-Bar virus-induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1
Host Species:
Mouse
Purification Method:
Protein A or G purified
Regulatory Status:
RUO
Primary or Secondary:
Primary
Target Species:
Human
Isotype:
IgG1 κ